Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118


β-Catenin is required for Ron receptor-induced mammary tumorigenesis.

Wagh PK, Gray JK, Zinser GM, Vasiliauskas J, James L, Monga SP, Waltz SE.

Oncogene. 2011 Aug 25;30(34):3694-704. doi: 10.1038/onc.2011.86. Epub 2011 Mar 21.


HGFL supports mammary tumorigenesis by enhancing tumor cell intrinsic survival and influencing macrophage and T-cell responses.

Benight NM, Wagh PK, Zinser GM, Peace BE, Stuart WD, Vasiliauskas J, Pathrose P, Starnes SL, Waltz SE.

Oncotarget. 2015 Jul 10;6(19):17445-61.


Conditional deletion of β-catenin in mammary epithelial cells of Ron receptor, Mst1r, overexpressing mice alters mammary tumorigenesis.

Wagh PK, Zinser GM, Gray JK, Shrestha A, Waltz SE.

Endocrinology. 2012 Jun;153(6):2735-46. doi: 10.1210/en.2011-1543. Epub 2012 Apr 2.


The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers.

Privette Vinnedge LM, Benight NM, Wagh PK, Pease NA, Nashu MA, Serrano-Lopez J, Adams AK, Cancelas JA, Waltz SE, Wells SI.

Oncogene. 2015 Apr 30;34(18):2325-36. doi: 10.1038/onc.2014.173. Epub 2014 Jun 23.


Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

Wagh PK, Peace BE, Waltz SE.

Adv Cancer Res. 2008;100:1-33. doi: 10.1016/S0065-230X(08)00001-8. Review.


Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation.

Zinser GM, Leonis MA, Toney K, Pathrose P, Thobe M, Kader SA, Peace BE, Beauman SR, Collins MH, Waltz SE.

Cancer Res. 2006 Dec 15;66(24):11967-74.


Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway.

Danilkovitch-Miagkova A, Miagkov A, Skeel A, Nakaigawa N, Zbar B, Leonard EJ.

Mol Cell Biol. 2001 Sep;21(17):5857-68.


Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer.

Peace BE, Toney-Earley K, Collins MH, Waltz SE.

Cancer Res. 2005 Feb 15;65(4):1285-93.


Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines.

McClaine RJ, Marshall AM, Wagh PK, Waltz SE.

Neoplasia. 2010 Aug;12(8):650-8.


The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer.

Zhao H, Chen MS, Lo YH, Waltz SE, Wang J, Ho PC, Vasiliauskas J, Plattner R, Wang YL, Wang SC.

Oncogene. 2014 Mar 13;33(11):1429-37. doi: 10.1038/onc.2013.84. Epub 2013 Apr 1.


Hepatocyte growth factor-like protein is a positive regulator of early mammary gland ductal morphogenesis.

Gurusamy D, Ruiz-Torres SJ, Johnson AL, Smith DA, Waltz SE.

Mech Dev. 2014 Aug;133:11-22. doi: 10.1016/j.mod.2014.07.002. Epub 2014 Jul 15.


Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer.

Pond AC, Herschkowitz JI, Schwertfeger KL, Welm B, Zhang Y, York B, Cardiff RD, Hilsenbeck S, Perou CM, Creighton CJ, Lloyd RE, Rosen JM.

Cancer Res. 2010 Jun 15;70(12):4868-79. doi: 10.1158/0008-5472.CAN-09-4404. Epub 2010 May 25.


Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.

Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ, Ellis LM.

Cancer. 2007 Mar 15;109(6):1030-9.


Loss of TGF-beta or Wnt5a results in an increase in Wnt/beta-catenin activity and redirects mammary tumour phenotype.

Roarty K, Baxley SE, Crowley MR, Frost AR, Serra R.

Breast Cancer Res. 2009;11(2):R19. doi: 10.1186/bcr2244. Epub 2009 Apr 3.


Myc is required for β-catenin-mediated mammary stem cell amplification and tumorigenesis.

Moumen M, Chiche A, Decraene C, Petit V, Gandarillas A, Deugnier MA, Glukhova MA, Faraldo MM.

Mol Cancer. 2013 Oct 30;12(1):132. doi: 10.1186/1476-4598-12-132.


Supplemental Content

Support Center